PARP1 and posterior cortical atrophy: As an example, a current clinical trial combining talazoparib—an inhibitor of PARP (Poly (ADP-Ribose) Polymerase 1)—with androgen deprivation therapy and abiraterone acetate to treat patients with metastatic castration-sensitive PCa seeks to determine the effect of androgen receptor genetic variations on PSA nadir as a secondary outcome measure (156).